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Background: Management of multidrug-resistant TB (MDR-TB) patients co-infected with human immuno-
deficiency virus (HIV) is highly challenging. Such patients are subject to long and potentially toxic treatments
and may develop a number of different psychiatric illnesses such as anxiety and depressive disorders. A mental
health assessment before MDR-TB treatment initiation may assist in early diagnosis and better management
of psychiatric illnesses in patients already having two stigmatising and debilitating diseases.
Objective: To address limited evidence on the baseline psychiatric conditions of HIV-infected MDR-TB
patients, we aimed to document the levels of depressive symptoms at baseline, and any alteration follow-
ing individualized clinical and psychological support during MDR-TB therapy, using the Patient Health
Questionnaire-9 (PHQ-9) tool, among HIV-infected patients.
Design: This was a retrospective review of the medical records of an adult (aged 15 years) HIV/MDR-TB
cohort registered for care during the period of August 2012 through to March 2014.
Results: A total of 45 HIV/MDR-TB patients underwent baseline assessment using the PHQ-9 tool, and seven
(16%) were found to have depressive symptoms. Of these, four patients had moderate to severe depressive
symptoms. Individualized psychological and clinical support was administered to these patients. Reassess-
ments were carried out for all patients after 3 months of follow-up, except one, who died during the period.
Among these 44 patients, three with baseline depressive symptoms still had depressive symptoms. However,
improvements were observed in all but one after 3 months of follow-up.
Conclusion: Psychiatric illnesses, including depressive symptoms, during MDR-TB treatment demand atten-
tion. Routine administration of baseline mental health assessments by trained staff has the potential to assist
in determining appropriate measures for the management of depressive symptoms duringMDR-TB treatment,
and help in improving overall treatment outcomes. We recommend regular monitoring of mental health status
by trained counsellors or clinical staff, using simple, validated and cost-effective tools.
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T
he human immunodeficiency virus (HIV) is a
driving force behind the global burden of tubercu-
losis (TB) and the development of drug-resistant
tuberculosis (DR-TB). Management of multidrug-resistant
TB (MDR-TB) patients co-infected with HIV is highly
challenging. With growing evidence showing psychiatric
illnesses such as depression, anxiety and psychosis to
be associated with MDR-TB (1, 2) and HIV (3), mental
health care for patients with these two stigmatising and
debilitating diseases demands attention.
AnMDR-TB patient co-infected with HIV is subject to
long and potentially toxic treatment that may make the
patient debilitated (4), stressed, and de-motivated. Addi-
tionally, dependence on the family for support, discrimi-
nation, and/or financial problems can further influence
the mental wellbeing of patients. These may develop into
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a number of psychiatric illnesses such as anxiety and depres-
sive disorders, which may lead to suboptimal adherence
to both antiretroviral (3, 5) and anti-TB treatments (2),
and ultimately poor treatment outcomes.
The baseline mental health characteristics of patients
may determine the development of subsequent psychiatric
conditions. A mental health assessment before MDR-TB
treatment initiation may thus assist in better management
of psychiatric illnesses and improve treatment outcomes
(6, 7). While psychiatric adverse events occurring during
the course of treatment have been well documented (1),
limited evidence exists on the baseline psychiatric con-
ditions of HIV-infected MDR-TB patients. To address
this evidence gap, we aimed to document the levels of
depressive symptoms at baseline, and any alteration follow-
ing clinical and psychological support during MDR-TB
treatment, among a cohort of HIV-infected MDR-TB
patients attending a clinic in Mumbai, India.
Methods
Study design
This study involves a retrospective review of the medical
records of an adult cohort (aged 15 years) of MDR-TB
patients co-infected with HIV.
Setting and study population
The Me´decins Sans Frontie`res (MSF) Clinic in Mumbai,
India provides individualized care to MDR-TB patients,
as described elsewhere (8). Psychological assessments
are carried out using the Patient Health Questionnaire-9
(PHQ-9) tool. The PHQ-9 tool, a nine-item checklist, has
been widely used for the assessment of depressive symp-
toms (9), including in TB patients (10). Together with other
clinical assessments, it is administered by trained MSF
counsellors at baseline (i.e. before or on the day of MDR-
TB treatment initiation) and every 3months during follow-
up afterMDR-TB treatment initiation. For the purpose of
our study, any patient found to have a score 4 using this
tool was defined as having depressive symptoms. The levels
of depressive symptoms were classified as mild (PHQ-9
score: 59), moderate (1014), moderately severe (1519)
and severe (2027) (10). A patient with a PHQ-9 score B5
was considered to be ‘without depressive symptoms’.
All the patients are managed by a multidisciplinary
team consisting of trained physicians, nurses, social work-
ers and psychologists (1). Treatment education is provided
to every patient, along with their family member/partner,
during treatment initiation and follow-up. Treatment is
provided to patients considering pharmacological inter-
actions between medications of three illnesses: alteration
of doses of medications and/or MDR-TB regimen itself,
if required. Individual counselling sessions are carried out
for patients with depressive symptoms, addressing stress,
poor adherence, and/or low motivation. A psychiatrist is
on-board for advanced clinical care of these patients. If
needed, patients receive psychiatric consultations with/
without medications during the treatment.
All HIV-infected MDR-TB patients aged 15 years
registered at the MSF clinic for treatment from August
2012 to March 2014 were included in the study. Patients
without depressive symptoms assessment before MDR-
TB treatment initiation using PHQ-9 tool, were excluded
from the analysis.
Data collection and analysis
Demographics, social and clinical data including age, sex,
literacy level, marital status, family income, family support,
previous TB episodes, TB resistance pattern and antiretro-
viral treatmentwere collected from routine programmedata
and from there, data were double-entered using EpiData
(version 3.1, EpiDataAssociation, Odense, Denmark) and
validated. Baseline and 3-month follow-up data of ‘depres-
sive symptoms’ for each patient were analysed.
Ethics
The study received approval from the MSF Ethics Review
Board in Geneva, Switzerland and the Ethics Advisory
Group of the International Union Against Tuberculosis
and Lung Disease, Paris, France. As this was a study of
routinely collected monitoring data, informed consent
from the patients was not obtained. The named ethics
committee waived the need for consent.
Results
During the study period, a total of 61 HIV/MDR-
TB patients were registered for care in clinic (Fig. 1).
Of these, 45 patients underwent baseline depressive symp-
toms assessment using the PHQ-9 tool: seven (16%)
patients had depressive symptoms while 38 did not have
baseline depressive symptoms. Baseline depressive symp-
tom levels could not be assessed for the other 16 patients
due to either the severity of their illness at treatment
initiation (6), or the low priority accorded to the assess-
ment by the counsellors (10).
Out of the seven patients with baseline depressive
symptoms, five had previous TB episodes (Table 1). Two
patients had MDR-TB, three had pre-extensively drug-
resistant TB (Pre-XDR-TB) and one patient each had
extensively drug-resistant TB (XDR-TB) and extremely
drug-resistant TB (X-XDR-TB), respectively. Individua-
lized psychological and clinical support was offered/
administered to patients (see Table 1).
Reassessments were carried out using the PHQ-9 tool
for all patients after 3 months of follow-up (Fig. 1), except
one, who died during the period. Among these 44 patients,
three patients (with baseline depressive symptoms) still
had depressive symptoms. However, improvements in
depressive-symptoms were observed in all but one patient
(Table 1).
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Discussion
Our study showed that about one-fifth of our HIV/
MDR-TB co-infected patients had baseline depressive
symptoms, which were managed with individualized psy-
chological and clinical support interventions.
Psychiatric illnesses have previously been documented
as an adverse event during MDR-TB treatment (1), and
have been associated with poor treatment outcomes in TB
patients (7, 11). Depression is one of the most common
psychiatric illnesses found in both HIV-infected patients
(3) and those under MDR-TB treatment (2). However,
despite being described as a major psychiatric condition
in pre-therapy MDR-TB patients (2), no baseline assess-
ments of depression have been reported among HIV/
MDR-TB patients.
In our study, all but one patient with baseline depressive
symptoms improved after 3 months of MDR-TB treat-
ment. Further, none of the patients had newly developed
depressive symptoms after 3 months of follow-up. Thus,
routine administration of baseline and follow-up mental
health assessments in MDR-TB patients has the potential
to assist in identifying those with psychiatric illness and
in need of appropriate measures for their management
during MDR-TB treatment, which could in turn improve
overall treatment outcomes (6, 7).
The treatment of depressive symptoms in HIV/MDR-
TB patients needs strategic selection of medications and/
or dosages for all three illnesses, including considera-
tion of possible pharmacological interactions. Some anti-
depressants, when administered to HIV-infected patients,
may exacerbate certain symptoms associated with HIV
(12). Similar pharmacological interactions have been docu-
mented between isoniazid and anti-depressants (13) for
tuberculosis patients. Thus, there is an urgent need for
simple, low pill burden, patient friendly regimens for HIV/
MDR-TB co-infected patients suffering from depressive
symptoms.
A strength of this study was the use of a standardized,
validated tool (PHQ-9) (9) by trainedMSF counsellors for
the assessment of depressive symptoms. While the small
Patients without depressive
symptoms at baseline (n=38)
Patients with depressive
symptoms at baseline (n=7)
After 3 months
Patient without 
depressive
symptoms
(n=37)
Patient without
depressive
symptoms
(n=4)
Patient with
depressive
symptoms
(n=3)
Patient died
(n=1)
Cohort of eligible HIV/MDR-TB patients
(n=61)
Excluded (n=16): 
- Patients had adverse outcomes (4 died,
  2 LTFU) before PHQ-9 administration
  (n=6)
- Patients without PHQ-9 assessment at
  baseline (n=10)
HIV/MDR-TB patients with baseline
PHQ-9 assessment (n=45)
Fig. 1. HIV/MDR-TB patients with depressive symptoms, using the PHQ-9 tool in an MSF clinic in Mumbai, India
(August 2012March 2014).
HIV/MDR-TB: HIV and multi-drug resistance tuberculosis co-infection; LTFU: loss-to-follow-up; PHQ-9: Patient Health
Questionnaire-9
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sample size is a limitation, the patients represent part
of the largest HIV/MDR-TB cohort in India. Another
limitation was that baseline depressive symptom assess-
ments were not carried out for all patients, due to severity
of the patients’ condition at registration in some or lack
of priority accorded by the counsellors in other cases.
The team felt that more attention was required to first
hospitalize/stabilize these patients (clinically or/and emo-
tionally), than carrying out their psychological assessment
using the tool. The latter highlights a major challenge
towards administration of a PHQ-9 tool, and the need
for well-trained counsellors in a programmatic setting; the
former suggests that, as patients in a very severe condition
may be more likely to suffer from depressive symptoms,
the prevalence of depressive symptoms may be under-
reported in our study.
Regular monitoring of the mental health status at
baseline and during MDR-TB treatment may help treat-
ment providers, patients and family members in appro-
priate management of a person’s condition during the
different stages of illness. Simple, cost-effective, and
easy-to-administer tools are required in order to facilitate
accurate monitoring of these patients. A number of mental
health assessment tools (6, 7, 11) including the PHQ-9
checklist (10, 14) have been identified for tuberculosis
patients. However, concerns have been raised about the
appropriateness of PHQ-9 checklist as a diagnostic tool
(15) and about its use for the Asian Indian population
(16). A setting-specific, validated tool is a key require-
ment for accurate mental health assessments in MDR-TB
patients.
Psychiatric co-morbidities are not a contra-indication
to MDR-TB treatment, as described by Vega et al.
(2). However, caution should be exercised during the
treatment of depressive symptoms in MDR-TB patients
receiving a regimen inclusive of cycloserine: it may be
difficult to differentiate between drug-induced psycholo-
gical complaints (2) and/or identification of pharmacolo-
gical interactions between MDR-TB medications and
anti-depressants. Care should be individually tailored to
Table 1. HIV/MDR-TB patients with baseline depressive symptoms attending MSF clinic, Mumbai, India (August 2012March
2014)
Case Age Sex
Family
support
Number of
previous
TB
episode(s)
Patient
on ART
during
treatment
TB
Resistance
pattern
Baseline depressive
symptoms status
(PHQ-9 score
out of 27)
Support
administered
Intermediate mental
health outcomes (after
3 months) (PHQ-9
score out of 27)
1 47 F Present 3 Yes MDR Mild (5) - Individual counselling
(motivation & emotional)
Improved (0)
2 35 M Absent 2 Yes Pre-XDR Severe (20) - Psychiatric consultation
with medication
- Individual counselling
(motivation & emotional)
Same as before (18)
3 47 M Present 1 Yes XDR Mild (6) - Individual counselling
session (motivation)
- Treatment education
involving AE
Improved (0)
4 36 M Present 2 Yes X-XDR Moderately
severe (16)
- Psychiatric consultation
with medication
- Individual counselling
session (motivation)
Improved (12)
5 27 F Absent 0 Yes Pre-XDR Moderate (11) - Psychiatric consultation
without medication
- Emotional support
Improved (3)
6 35 M Present 1 Yes Pre-XDR Moderate (11) - Individual counselling
session (motivation)
Improved (9)
7 16 F Present 0 Yes MDR Mild (5) - Emotional support Improved (4)
M: male; F: female; TB: tuberculosis; AE: adverse events during treatment; MDR-TB: multidrug-resistant tuberculosis; Pre-XDR-TB:
pre-extensively drug-resistant tuberculosis; defined as MDR-TB case whose recovered M. tuberculosis isolate is resistant to at least
isoniazid, rifampicin, and either a fluoroquinolone or a second-line injectable anti-TB drug; XDR-TB: extensively drug-resistant
tuberculosis; X-XDR-TB: Extremely drug-resistant tuberculosis; defined as MDR-TB case whose recovered M. tuberculosis isolate is
resistant to all first-line and second-line anti-TB drugs.
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help patients cope with the combined burden of depressive
symptoms in addition to their existing debilitating, stig-
matising diseases of HIV and MDR-TB (4).
Conclusion
Psychiatric illnesses during MDR-TB treatment, includ-
ing depressive symptoms, demand attention. The clinical
staff involved in management ofMDR-TB patients should
be trained to administer appropriate mental health assess-
ment tools, especially at baseline, so that psychiatric dis-
orders can be identified early. We recommend regular
monitoring of mental health status by trained counsellors
or clinical staff, using simple, validated and cost-effective
tools.
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